# Luca Binda PhD MBA

> Luca Binda PhD MBA is a funding round investor at TechWald Holding S.p.A. backing Health Care. See 15 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [TechWald Holding S.p.A.](https://shizune.co/investors/profile/techwald-holding-s-p-a)
- Location: Milano, Italy
- Total investments: 15
- Last investment: Sep 2018
- Lead investor: 20%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/bindaluca/

Luca Binda PhD MBA is a funding round investor at TechWald Holding S.p.A. in Milano focused on Health Care and Manufacturing. Dr Luca Binda is managing partner and investment director of TechWald Holding (Italy & Israel), a participation holding company active in medtech in Israel, Europe and US. He also is an executive director of a number of medtech start up corporations. From 2009 to 2018 he was senior investment manager of the Venture Capital firm IMI Fondi Chiusi(Italy) focusing on investments in medtech. Previously he was senior scientist at ETHZurich (Switzerland) in the field of modelling and simulation of mechanical systems and product engineer lead at Alfa Romeo S.p.A. (Italy). He earned a MBA from SDA Bocconi (Italy), a PhD in mechanical engineering from ETH Zurich (Switzerland) and a MSc from Politecnico di Milano (Italy).

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 4 | 27% |
| Manufacturing | 4 | 27% |
| Medical Device | 4 | 27% |
| Medical | 3 | 20% |
| Sensor | 1 | 7% |

17 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Funding Round | 5 | 33% |
| Seed | 2 | 13% |
| Series A | 2 | 13% |
| Series C | 1 | 7% |
| Convertible Note | 1 | 7% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Italy | 4 | 27% |
| Israel | 3 | 20% |
| United States | 1 | 7% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| NitiNotes | Nitinotes has developed the EndoZipTM, a fully automated, operator independent gastroscopic suturing system, allowing gastroenterologists as well as surgeons to bring a durable solution to their patients. The procedure creates an effect of stomach volume restriction and motility impair - both are needed to help obese patients reducing weight. | $7.1M | Series A | Mar 25, 2020 |  |
| Bendit | Bendit is a medical company that develops and manufactures innovative catheters based on a unique bending technology, enabling extensive steering abilities in micro diameter and conventional catheter wires and tubes. The company is a joint venture between three experienced groups from production, quality & regulation, and development in themedical field. | $2M | Convertible Note | Jun 01, 2018 |  |
| Bendit | Bendit is a medical company that develops and manufactures innovative catheters based on a unique bending technology, enabling extensive steering abilities in micro diameter and conventional catheter wires and tubes. The company is a joint venture between three experienced groups from production, quality & regulation, and development in themedical field. | $3.6M | Series A | Sep 03, 2017 |  |
| Newronika | Newronika restores brain and body functions with innovative technologies. We translate our deep knowledge on biosignal decoding into clinical practice, with the aim of improving treatments, health, and wellness. With our revolutionary brain devices, the patient receives the right stimulation at the right moment, thus becoming able to perform normaldaily activities and improve quality of life. Newronika is the spin-off company of two leading research institutions in Italy, the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Hospital and the University of Milan. ​ Newronika comprises a multidisciplinary team formed from Neuroscience research groups and involves scientists with expertise in neurophysiology, neurology, biomedical engineering, neuropsychology, bioinformatics, and biotechnologies. | $1.9M |  | Jun 14, 2016 |  |
| Newronika | Newronika restores brain and body functions with innovative technologies. We translate our deep knowledge on biosignal decoding into clinical practice, with the aim of improving treatments, health, and wellness. With our revolutionary brain devices, the patient receives the right stimulation at the right moment, thus becoming able to perform normaldaily activities and improve quality of life. Newronika is the spin-off company of two leading research institutions in Italy, the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Hospital and the University of Milan. ​ Newronika comprises a multidisciplinary team formed from Neuroscience research groups and involves scientists with expertise in neurophysiology, neurology, biomedical engineering, neuropsychology, bioinformatics, and biotechnologies. |  | Seed | Mar 01, 2016 |  |
| Pi-Cardia | Pi-Cardia is a medical device start-up company developing a novel low profile catheter for the treatment of aortic stenosis. The company's proprietary technology is based on delivering mechanical impact for creating fractures in valve calcifications, without injuring the surrounding soft tissue. This treatment, which only takes severalseconds, is intended to increase the valve effective orifice area without the need to replace the valve. | $10M | Series C | Jan 07, 2016 |  |
| Pi-Cardia | Pi-Cardia is a medical device start-up company developing a novel low profile catheter for the treatment of aortic stenosis. The company's proprietary technology is based on delivering mechanical impact for creating fractures in valve calcifications, without injuring the surrounding soft tissue. This treatment, which only takes severalseconds, is intended to increase the valve effective orifice area without the need to replace the valve. |  | Series C | Sep 01, 2015 |  |
| MilkyWay | Milky Way is a name which well represents the idea of what we intended to realize: «a new galaxy of other world components… brilliant and innovative components aimed to minimize the result of the magic formula: “(weight/resistance)*cost” ».Our strenght is the Made in Italy. We pursue this aim every day working with Italian machineries, andtrying to innovate not only products but also the production processes. |  |  | Jul 22, 2015 |  |
| Nextatlas | Nextatlas helps brands easily visualize emerging trends by meshing together data from a wide variety of sources into actionable insights that inform and inspire the creative process. Nextatlas lets professionals of the most innovative brands view, interact with, and export real-time trend reports and data in a beautiful and intuitive way.Nextatlas is a business application for data-driven inspiration. Using finely tuned algorithms, it offers brands a new way to identify emerging consumer trends and fuels strategy with visually stunning trend forecasts. Also, Nextatlas provides real time information that can be quickly exported into beautiful, inspiring, and completely customizable trend reports.Nextatlas is a product of iCoolhunt SpA. iCoolhunt is a pioneering proponent of innovative services that provide brand owners and their key advisors with rich, timely and objective information about the drivers of change in consumer lifestyles and behavior. |  |  | Mar 31, 2015 |  |
| SEMPLUS | SEM+ is an hi-tech start-up company providing reliable and unobtrusive pressure sensitive solutions while enabling the development of the next-generation of flexible hi-tech devices.Sensors implementing our technology are mechanically reliable and robust, and are able to reconstruct the map of pressure distributions applied on their sensitivesurfaces, as well as the intensity of multiple contacts. |  |  | Nov 20, 2014 |  |

10 of 15 investments shown.

## Co-investors
- [Indaco Venture Partners](https://shizune.co/investors/profile/indaco-venture-partners) — VC Fund, 2 deals together
- [Innogest Capital](https://shizune.co/investors/profile/innogest-sgr) — VC Fund, 2 deals together
- [Clal Biotechnology Industries](https://shizune.co/investors/profile/clal-biotechnology) — VC Fund, 1 deal together
- [Fondamenta SGR](https://shizune.co/investors/profile/fondamenta-sgr) — VC Fund, 1 deal together
- [Italian Angels for Growth](https://shizune.co/investors/profile/italian-angels-for-growth) — VC Fund, 1 deal together
- [MTIP AG](https://shizune.co/investors/profile/medtech-innovation-partners) — VC Fund, 1 deal together

## About TechWald Holding S.p.A.

VC Fund · Milan, Italy

TechWald Holding is a participation holding company investing in Medical Technologies

1 contacts available at TechWald Holding S.p.A..

| Name | Title | Profile |
| --- | --- | --- |
| Luca Binda PhD MBA | Managing Partner & Investment Director | https://shizune.co/investors/profile/luca-binda |

## Similar investors

### Similar stage
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund

## FAQ

### What does Luca Binda PhD MBA invest in?

Luca Binda PhD MBA invests primarily in Health Care, Manufacturing and Medical Device startups, most often at Funding Round and Seed stage. Most of the 15 investments tracked by Shizune back companies in Italy. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Luca Binda PhD MBA last invest?

The most recent investment recorded for Luca Binda PhD MBA closed in Sep 2018. Shizune tracks 15 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co